Imperial Confidence in Concept

Lead Research Organisation: Imperial College London
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

Imperial Confidence in Concept: ICIC7

Publications

10 25 50

publication icon
Kedrzycki MS (2023) Guidance in breast-conserving surgery: tumour localization versus identification. in The British journal of surgery

publication icon
Mielcarek M (2021) Polyglutamine diseases: looking beyond the neurodegenerative universe. in Neural regeneration research

 
Title ICiC 7 - Maitland - MIMBLE film local made nutrition feeds for malnutrition 
Description Film about nutrition feeds 
Type Of Art Film/Video/Animation 
Year Produced 2023 
Impact none- film still in draft mode 
URL https://vimeo.com/784346152/4223ef8c98
 
Description DT-Prime award - Isalan - ICiC 7
Amount £101,856 (GBP)
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 02/2022 
End 07/2022
 
Description ICiC - Masouros - EPSRC Impact Accelerator Award
Amount £70,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 03/2021
 
Description ICiC 7 - Farina - H2020 EUROBENCH FSTP-2
Amount € 59,992 (EUR)
Funding ID P90050 
Organisation Spanish National Research Council (CSIC) 
Sector Public
Country Spain
Start 08/2021 
End 05/2022
 
Description ICiC 7 - French - CRUK Convergence Science Centre Clinical Academic Training Programme Intercalated PhD Award in 2020
Amount £117,019 (GBP)
Funding ID C309/A31316 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 06/2023
 
Description ICiC 7 - French - Knowledge Transfer Secondment (KTS) from EPSRC Impact Acceleration Account at Imperial
Amount £15,126 (GBP)
Funding ID EP/R511547/1 
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 09/2019 
End 12/2019
 
Description ICiC 7 - French - Silicon Valley Community Foundation - CZI Advancing Imaging Through Collaborative Projects Progress Report
Amount $349,871 (USD)
Organisation Silicon Valley Community Foundation 
Sector Charity/Non Profit
Country United States
Start 03/2023 
End 02/2025
 
Description ICiC 7 - Leff - The Hamlyn Accelerator for Surgical Innovation
Amount £49,888 (GBP)
Funding ID PSZo87 NQHAM 
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 04/2021 
End 04/2022
 
Description ICiC 7 - Maitland - Research England - International Science Partnerships Fund (ISPF) 2023/24 Global Development Hub ODA Project Accelerator
Amount £60,200 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 02/2024 
End 07/2024
 
Description ICiC 7 - Maitland - UKRI GCRF and Newton Consolidation Accounts GNCA
Amount £50,411 (GBP)
Funding ID PSO023_WRDN 
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 09/2022 
End 03/2023
 
Description ICiC 7 - Masouros - Impact Accelerator Award UKRI (EPSRC)
Amount £80,606 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2023 
End 03/2024
 
Title Effect of ECM on zonal hepatocyte maturation and function - ICiC 7 - Baum 
Description We found that collagen and matrigel affect hESC-derived hepatocytes to have distinct functions reflecting hepatocytes of different spatial location in the liver lobule. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2023 
Provided To Others? Yes  
Impact our findings, together with tissue engineering technology, could facilitate the generation of liver tissues that resemble the liver lobular structure by applying different ECMs along the periportal-pericentral axis. 
 
Title ICIC 7 - French - Super-resolved immunofluorescence applied to histopathology of kidney disease 
Description We demonstrated the potential to use super-resolved immunofluorescence for the diagnosis of kidney disease, viewing ultrastructure not accessible with conventional immunofluorescence 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact Super-resolved immunofluorescence may provide a low-cost alternative to electron microscopy for histopathology - potentially enhancing the diagnosis of kidney disease where EM is not available. 
 
Title ICiC 7 - Farina - MyoLink High Density sEMG recording system 
Description Multi-channel sEMG recording device with noise floor of <0.4uVrms - lower than currently available commercial systems. (Feb 2023) 
Type Of Material Improvements to research infrastructure 
Year Produced 2022 
Provided To Others? Yes  
Impact Increased number of observed neural activity 
URL https://pubmed.ncbi.nlm.nih.gov/35468056/
 
Title ICiC 7 - French - OpenFrame 
Description We have continued to develop open-source microscopes 
Type Of Material Improvements to research infrastructure 
Year Produced 2023 
Provided To Others? Yes  
Impact paper, online resources 
URL https://www.imperial.ac.uk/photonics/research/biophotonics/instruments--software/fluorescence-micros...
 
Title ICiC 7 - Tate - Assay development 
Description We developed a time course cell-based assay to assess the ability of compounds to inhibit CD59 function 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? No  
Impact We developed a time course cell-based assay to assess the ability of compounds to inhibit CD59 function 
 
Description ICiC 7 - French - Carin Research Ltd 
Organisation CAIRN Research Ltd
Country United Kingdom 
Sector Private 
PI Contribution We worked with Cairn Research Instruments in developing our open source microscopy tools, including the openFrame platform. Cairn also manufacture and sell components that can be used to assemble the low-cost histoSTORM microscope that we developed. This enables other laboratories to replicate our work.
Collaborator Contribution Cairn worked with us to finalise the design of the openFrame microscope, which they now sell. The design is open source and CAD files are freely available.
Impact Cairn are able to manufacture and sell components to customers wishing to assemble their own microscope systems
Start Year 2019
 
Description ICiC 7 - French - IITG 
Organisation Indian Institute of Technology Guwahati
Country India 
Sector Academic/University 
PI Contribution We sent an openFrame microscope system to IITG supported by a parallel Imperial GCRF grant and we will transfer expertise developed during this ICiC project to IITG to apply this to (super-resolved immunofluorescence) histopathology
Collaborator Contribution N/A
Impact IITG will be able to undertake research into the development and application of cost-effective microscope systems for histopathology, including super-resolved immunofluorescence, which could be useful, e.g. to help diagnose kidney disease where clinical electron microscopy is not available.
Start Year 2019
 
Description ICiC 7 - French - openScopes Africa 
Organisation University of Cape Town
Department Institute of Infectious Disease and Molecular Medicine (IIDMM)
Country South Africa 
Sector Academic/University 
PI Contribution Developing open-source cost-effective research-grade microscopes for Africa, including for pathology and study of TB
Collaborator Contribution They are the end users and experts in TB
Impact N/A
Start Year 2023
 
Description ICiC 7 - Larrouy-Maumus - Consolidate collaboration agreement with Bruker microbiology 
Organisation Brucker
Country United States 
Sector Private 
PI Contribution MALDI measurements
Collaborator Contribution MALDI knowledge and access to MALDI equipment hosted in my laboratory
Impact N/A
Start Year 2023
 
Description ICiC 7 - Leff - "AHA" 
Organisation Photonamic
Country Germany 
Sector Private 
PI Contribution We have offered to trial the ALA in a 40-patient feasibility study.
Collaborator Contribution Photonamic GmbH have contributed 60 vials of ALA.
Impact N/A
Start Year 2021
 
Description ICiC 7 - Maitland - MIMBLE 3 trial grant 
Organisation Tropical Gastroenterology & Nutrition group (TROPGAN)
Country Zambia 
Sector Charity/Non Profit 
PI Contribution Development of a trial grant
Collaborator Contribution Expertise in gut health and biomakers
Impact None
Start Year 2022
 
Description ICiC 7 - Masouros - UoS 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution N/A
Collaborator Contribution They provided advice for us, and carried out tests with our device. We applied together (with me as the PI) to NIHR for further funding.
Impact N/A
Start Year 2019
 
Description ICiC 7 - Masouros - tissue viability nurse 
Organisation National Health Service
Country United Kingdom 
Sector Hospitals 
PI Contribution none
Collaborator Contribution Research nurse time
Impact none
Start Year 2022
 
Title ACTIVE DELIVERY OF NUCLEIC ACIDS AND PEPTIDES, METHODS AND USES 
Description Disclosed herein are polypeptides for use in treating diseases. Therapeutic uses and methods for treating diseases are also disclosed. Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro. 
IP Reference WO2022003363 
Protection Patent application published
Year Protection Granted 2022
Licensed No
Impact We are looking to using it to set up a start-up
 
Title CELL THERAPY 
Description The present invention relates to methods for the production of immune cells and immunomodulatory cells expressing a transgene of interest, using lentiviral vectors. The invention also relates to populations of cells produced by such methods and uses thereof. 
IP Reference WO2022219336 
Protection Patent / Patent application
Year Protection Granted 2022
Licensed No
Impact N/A
 
Title DEVICE FOR SUPPORTING A BODY PART 
Description A method of supporting a body part (16), comprising providing a device (100) comprising: a first portion (105) configured to support a body part, wherein, in use, the body part applies a first pressure to the first portion in a first direction; means for detecting the first pressure; and a second portion (115) having means (212) for applying a second pressure to the body part in a second direction substantially perpendicular to the first direction; detecting the first pressure; determining the second pressure based on a user parameter; and applying the second pressure to the body part in the second direction at a pre-determined ratio relative to the first pressure using said means for applying the second pressure. 
IP Reference WO2020053586 
Protection Patent / Patent application
Year Protection Granted 2020
Licensed No
Impact N/A
 
Title NMT INHIBITORS FOR TREATING SENESCENCE-ASSOCIATED DISEASES OR DISORDERS 
Description The present invention provides a NMT inhibitor for use in the prophylaxis or treatment of a senescence-associated disease or disorder. 
IP Reference WO2022090746 
Protection Patent / Patent application
Year Protection Granted 2022
Licensed Yes
Impact N/A
 
Title POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS 
Description The present disclosure relates to the provision of novel biodegradable amphiphilic peptides and peptide analogues based on poly(L-lysine isophthalamide)(PLP) derivatives comprising hydrophobic chains and their use in the permeabilization of mammalian cells and delivery of agents, for example therapeutic agents, imaging agents and cell preservation agents. 
IP Reference WO2018011580 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact N/A
 
Title THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES I 
Description Disclosed herein are polypeptides for use in treating diseases associated with pathogenic genomic repeat sequences, such as neurological disorders. Also disclosed are nucleic acid molecules and vectors that encode such polypeptides. Therapeutic uses and methods for treating such diseases are also disclosed; in particular, therapeutic uses and methods comprising complementary pairs and combinations of therapeutic polypeptides, nucleic acids or vectors. Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro. 
IP Reference WO2022003361 
Protection Patent application published
Year Protection Granted 2022
Licensed No
Impact We are looking to using it to set up a start-up
 
Title THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES II 
Description Disclosed herein are polypeptides for use in treating diseases associated with pathogenic genomic repeat sequences, such as neurological disorders. Also disclosed are nucleic acid molecules and vectors that encode such polypeptides. Therapeutic uses and methods for treating such diseases are also disclosed; in particular, therapeutic uses and methods comprising complementary pairs and combinations of therapeutic polypeptides, nucleic acids or vectors. Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro. 
IP Reference WO2022003362 
Protection Patent application published
Year Protection Granted 2022
Licensed No
Impact We are looking to using it to set up a start-up
 
Title ICiC 7 - French - Open source microscope applied to histopathology using super-resolved immunofluorescence: histoSTORM 
Description We developed an open source super-resolving immunofluorescence microscope and protocols to process frozen or FFPE histological sections. We performed STORM microscopy to obtain super-resolved immunofluorescence images of clinical histology sections from kidney tissue biopsies, which were compared to diagnostic EM images of tissue from the same biopsy. We demonstrated that histoSTORM provided added value to the standard brightfield and immunofluorescence images, indicting to replace EM in some situations - and to be useful where clinical diagnostic EM is not available 
Type Diagnostic Tool - Imaging
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2021
Development Status Actively seeking support
Impact We will apply for an NIHR i4i grant to develop the instrument for a clinical trial 
 
Title ICiC 7 - Stevens - SPARTA® platform development 
Description SPARTAÒ is a novel nanoparticle characterisation technology that enables the analysis of viral vectors for gene therapy applications. 
Type Support Tool - For Fundamental Research
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2022
Development Status Under active development/distribution
Impact N/A 
 
Title ICiC 7 - French - openFrame 
Description open-source microscope 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2022 
Open Source License? Yes  
Impact in use in India and South Africa 
URL https://www.imperial.ac.uk/photonics/research/biophotonics/instruments--software/fluorescence-micros...
 
Company Name SPARTA Biodiscovery 
Description SPARTA Biodiscovery develops the technology to research nanoparticles enabling nanoformulations for therapeutics. 
Year Established 2022 
Impact n/a
Website https://spartabiodiscovery.com/
 
Description ICiC 7 - French - Half term outreach activity for families 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact My group, including ICiC employed PDRA and my PhD students, have developed an activity to introduce the public - and specifically school children to microscopy and its application to medicine. We held a successful engagement event with primary school children and their families at White City on 02/06/2021, where this event had the highest attendance (30 children and parents) across a programme of half term activities.
Year(s) Of Engagement Activity 2021
 
Description ICiC 7 - French - Imperial Lates 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact We had a stand as part of Imperial Lates and members of public stopped by
Year(s) Of Engagement Activity 2023
 
Description ICiC 7 - Larrouy-Maumus - Invited speaker at national conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact invited speaker at 22nd conference in Genomics and Proteomics at Middlesex University
Year(s) Of Engagement Activity 2023
 
Description ICiC 7 - Maitland - Severe malnutrition Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Closed meeting to discuss management of severe malnutrition with international experts
Year(s) Of Engagement Activity 2023
 
Description ICiC 7 - Maitland - We met with WHO, World Food Programme and UNICEF about our philosophy for redesigning nutritional feeds which could be manufactured locally in African countries rather than being obtained from Europe/elsewhere 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact We held a teleconference with the policy makers and had a closed meeting in January 2023
which a number of stakeholders attended including WHO
Year(s) Of Engagement Activity 2023